AI assistant
Immuneering Corp — Director's Dealing 2022
Aug 11, 2022
32973_dirs_2022-08-11_bee807a3-aa91-45aa-91c3-67542582bbf1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2022-08-11
Reporting Person: Morales Mallory (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 2434 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $9.74 | 2031-05-10 | Class A Common Stock (25480) | Direct | |
| Stock Option | $9.66 | 2032-02-10 | Class A Common Stock (23850) | Direct | |
| Stock Option | $5.41 | 2032-06-30 | Class A Common Stock (5000) | Direct |
Footnotes
F1: The option vests and becomes exercisable as to 25% of the underlying shares on May 10, 2022 and then in equal monthly installments over the subsequent three years, subject to Ms. Morales' continued employment through each applicable vesting date.
F2: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026.
F3: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on July 31, 2022, and will be fully vested and exercisable on June 30, 2026.